cropper
update

Tom Jones Pharmacist LIVE Wellness BLOG

update
  • Tom Jones Pharmacist LIVE Wellness Blog
  • Subscribe
  • Contact Us
  • Tom Jones Pharmacist LIVE Wellness Blog
July 09.2022
5 Minutes Read

Giant Step For Pharmacists

Exciting News Everybody.

Pharmacists Are Very Accessible.

And Covid-19 Is Very Catchable.

When you add those 2 facts together, Sometimes you come up with big problems.

Pharmacists to the rescue. Officially, starting on this past week on July 6th, 2022,  Pharmacists now may prescribe under special conditions and special criteria, Paxlovid by prescription to the patient when the patient has confirmed Covid.  And what better professional to monitor and check for drug interactions and any precautions concerning Paxlovid.  What great news. 

discuss the announcement by the FDA that approves pharmacists’ prescriptive authority for the COVID-19 antiviral Paxlovid. what did the announcement from the FDA on Paxlovid entail exactly, and what are the implications of this announcement?

 pharmacists, as of this week, can now prescribe Paxlovid under the specific protocol, again, this was a not something that was written into the law, but it was actually written out of the FDA rule that excluded pharmacists, an information and document that, that they might be able to prescribe Paxlovid, again, within a specific window for patients who are COVID-19 positive.


Now, pharmacists today are doing some testing themselves, but this also means that a patient could walk right up and say, ‘I'm positive. Here's my test, and would you mind could you prescribe Paxlovid.’ That initiates essentially an evaluation by the pharmacist to determine whether or not that is effective. Such a big win for pharmacists, but more so for patients.

We expected this whenever Paxlovid EUA was approved months ago, and it was a shock to everyone that the FDA excluded pharmacists at the time

JULY 6, 2022 The PHARMACIST ROLE IN PAXLOVID THERAPY FOR COVID-19.  As potential patients need to know, the FDA has issued emergency authorization (“EUA”) for Pfizer’s Paxlovid, an oral antiviral, for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients.

On July 6, 2022, the FDA amended the Paxlovid EUA to state:

 

PAXLOVID may also be prescribed for an individual patient by a state-licensed pharmacist under the following conditions:

 

O   Sufficient information is available, such as through access to health records less than 12 months old or consultation with a health care provider in an established provider-patient relationship with the individual patient, to assess renal and hepatic function; and

O  Sufficient information is available, such as through access to health records, patient reporting of medical history, or consultation with a health care provider in an established provider-patient relationship with the individual 

patient, to obtain a comprehensive list of medications (prescribed and non-prescribed) that the patient is taking to assess for potential drug interaction.


Right now, this allows pharmacists to be able to prescribe for COVID during the public  what we're already seeing is both small market, mid-market, and large market—pharmacies are now engaging in planning on providing the same level of care for strep, the flu, and even RSV at times as well, as long as those state and federal regulations are met. So we're seeing a mass adoption right now of pharmacy to say, ‘We can help here.

 

Here are the rules and everyone must follow the rules and law entirely.  First and foremost, you must have a positive covid-19 test. You must have your 

Pharmacists make a difference. Not only in many states can pharmacists test, but now they can treat.   And that, as a patient, is key because as we're talking about trying to improve health equity in the rural, suburban, and even honestly, in the urban spaces, we need pharmacists, 

health emergency, but we need federal and state legislators to make that permanent.


 9 out of 10 Americans today live within 5 miles of a pharmacy

Again, if a pharmacist is going to stop what they're doing, evaluate the patient, gather lab data, including kidney function, and liver function, speak with other providers, at times, connect with the patient and do a full interview, gather the prescription fill history, they have to have a way to be reimbursed for that, otherwise, we will not see the adoption that we're all hoping, and it flies in the face of the pharmacist in solving the challenge of health equity.

So, we have to be able to have that conversation with payers. So this crossing the Rubicon 

 

The second thing that this forces a conversation with labs and pharmacies coming together. So, for the very first time, we have, again, the largest material needs ever for lab and pharmacy to connect that we've seen in our industry to date.


I would say that technology plays a key role here, we need to be able to take disparate data, and be able to tee it up for the pharmacists within their workflow. I think about the patient who walks into the pharmacy today, seeking a Paxlovid prescription. That pharmacist has just seen a patient to fill a prescription, the patient after that was the patient who needed a vaccination, and now I'm here to be able to serve that patient for Paxlovid, but now I need disparate data that's not in my system, I need to go get lab data.

So again, it's absolutely vital that my documentation, my communication with providers, my communication with lab updates, again, that's required by state and federal authorities, in this lab itself, like the test data again, I need that altogether. So technology is going to play a key role here if we're going to operationalize this on a scale that's necessary to meet the demands of America.


The last thing I would say is that, again, this is something that we're doing in partnership with physicians. We, as pharmacists, love our physician teams, and again, by no means is this pulling from them as we've seen in the reaction from the AMA. We respond to that and say, ‘We love our physicians.’ Again, we're here to be able to address together those health equity problems, and we'll seek to solve those together.

I fundamentally believe that this is taking our pharmacists back to their first love which is helping patients and engaging patients in a way that improves health outcomes as well. Our goal as pharmacists is to help our fellow citizens and improve their healthcare in the best and safest way possible to the best of our ability.

 

 



Click Here To Learn More

Covid-19

72 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
07.09.2022

Giant Step Forward For Your Pharmacist

Pharmacists to the rescue. Officially, starting on this past week on July 8th, 2022, Pharmacists now may prescribe under special conditions and special criteria, Paxlovid by prescription to you.

05.22.2022

Covid-19 and The New Wave, It is Number ???. Oh, Almost Nobody Cares Anymore.

The numbers are in and there were 171,191 new cases of Covid-19 with the 7 day average of 104,186 new cases per day this past week. I think that I must have misread the number

01.05.2022

Will We Need An Additional Fourth Vaccine Shot

Update  Although. conversations about fourth dosages are premature, research is increasingly. supporting the effectiveness of three doses versus the coronavirus. alternative Omicron. Nick Oxford/Bloomberg/Getty Images Research studies so far have revealed that just 2 doses of COVID-19 vaccines may not be as reliable against the Omicron variation. However,. information has indicated that boosting with an extra shot of the. COVID-19 vaccines might restore this protection to a level similar to what. the two-dose routine provided against other versions. Researchers stress presently that it's prematurely to speak about a fourth dosage or yearly immunization and more data is needed. Early reports recommend that the standard two doses. of COVID-19 vaccine may not offer enough protection versus. infection with the Omicron variation, regardless of still providing enough. security versus severe disease and death. This has accelerated. the rollout of boosters in numerous nations, with vaccine makers. Update announcing that they're working on variant-specific vaccines. Although. the need of 3 doses is emerging, it's less clear how. long that security lasts with antibodies waning with time. Whether. a 4th dose will become required to combat this-- and if so,. when it will be administered-- stays unidentified in the meantime. Here's what the professionals consider this possibility. A fourth shot, sooner than expected? Pfizer CEO Albert Bourla told CNBC. recently that a fourth dosage might be needed after initial research. revealed that the Omicron version can weaken the antibodies produced. by the COVID-19 vaccine. He also stated that we may need them sooner. rather than later on. " When we see real-world data, it will identify. if the Omicron is well covered by the third dosage and for how long. And. the 2nd point, I believe we will need a 4th dose," Bourla stated. Update " With Omicron we need to wait and see since we have extremely little info. We may need it quicker," he included. Regardless of. these remarks, the World Health Organization (WHO) hasn't chosen to. back a worldwide rollout of booster shots and has actually signified that more. data is needed before a decision is made. Another subject on the table is that of shortening the intervals between the second dose and booster shots. But Dr. Monica Gandhi,. an infectious diseases expert with the University of California,. San Francisco, said that research study indicates that giving them prematurely. will not supply as much advantage. " The data so far does assistance providing boosters 4 to 6 months after the 2nd dosage but spacing out dosages in fact increases immunogenicityTrusted Source, so I would not provide quicker than 12 weeks after the last dosage," she said. What we know: 3 dosages better versus Omicron At. Update the moment, there isn't enough data to definitively say whether we require. a 4th dosage. Nevertheless, an increasing variety of reports are revealing. that 3 doses will be essential for Omicron. Draft research study from Oxford. released today showed that simply 2 dosages of the AstraZeneca or. Pfizer vaccines offered little protection against an Omicron infection. " [L] aboratory. studies reveal that the Omicron variant could escape the neutralizing. activity of antibodies generated by the two-dose Pfizer vaccine. substantially, although those with previous infection then vaccination had. less escape," stated Gandhi. However, she mentioned that the. two-dose mRNA vaccines were still safeguarding individuals with the Omicron. variant from extreme illness, referring to a recent research study launched in South Africa. The. study found that 2 dosages supplied 70 percent protection against. hospitalization with Omicron and 33 percent security against. infection. These figures were 93 percent and 80 percent for the. coronavirus alternative Delta, respectively. Previous information. from Pfizer has revealed that administering a booster dose substantially. increases reducing the effects of antibodies, bringing the vaccine's security. near what 2 doses anticipated Delta. Similarly, an Israeli study. compared people who had their 2nd dosage 5 to 6 months earlier and those. who had actually received a booster about a month earlier. They found that a third. dose provided 100-fold protection against Omicron. An early analysis. from the United Kingdom also recommended that booster shots avoided 70. to 75 percent of individuals from getting any symptoms. They found a small. difference depending on whether the preliminary dosages were from the. Oxford-AstraZeneca vaccine or Pfizer-BioNTech vaccine. Based on information up until now, Gandhi stated that a fourth dose was unwarranted. " A third dosage will assist increase security however we do not yet have a reasoning for a fourth dosage," she informed Healthline. Click Here To Learn More

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*